In The News: School of Integrated Health Sciences
Alzheimer's treatments were not considered likely just months ago.
Alzheimer's treatments seemed like an unlikely prospect just months ago.
Air Force veteran Ally Schroeder has had nearly everything in her education and career path planned out for the last three years, so it’s stressful not to know whether she’ll have enough money for housing in January.
Air Force veteran Ally Schroeder has had nearly everything in her education and career path planned out for the last three years, so it’s stressful not to know whether she’ll have enough money for housing in January.
A recently approved medication for Alzheimer’s disease is making headlines because of its price tag. It costs $56,000 a year.
ANS is hosting a virtual Graduate School Fair on Friday, November 19, from 3:30 p.m. to 6:30 p.m. (EST). The goal of the event is to help prepare the next generation of nuclear professionals and to keep early career and seasoned experts at the top of their game.
Despite projections implying that the clinical use of aducanumab (Aduhelm; Biogen), the first drug approved for the treatment of Alzheimer disease (AD), would be widespread by this point, financial reports have indicated that the clinical use of the therapy is far below expectations.
reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.
More than 1100 people filled the Las Vegas Ballpark Saturday morning for the annual Alzheimer’s Association Walk to End Alzheimer’s.
BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a key opinion leader webinar on neuroinflammation and insulin resistance and new treatment approaches for Alzheimer’s Disease on Tuesday, October 26, 2021 at 1:30 pm Eastern Time.
Researchers looking for a pre-approved drug that can be reused to treat Alzheimer’s disease have found promising signs of efficacy in a 50-year-old generic drug commonly used as a diuretic.